CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Capricor Therapeutics, Inc. for alleged misrepresentations regarding the safety and efficacy data of its lead drug candidate, deramiocel, during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025 [1]. - The allegations focus on misrepresentations related to the four-year safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy [2]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file necessary documents by September 15, 2025, with the role involving representation of other class members in the litigation [3]. - Participation as a class member does not require serving as lead plaintiff, and all legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].